Your request to link to rcsb for Aldose reductase (AR)

---

• 1DLA: novel nadph-binding domain revealed by the crystal structure of aldose reductase (10.1038/355469A0 )
• 1EF3: fidarestat bound to human aldose reductase (10.1021/JM990502R )
• 1EKO: pig aldose reductase complexed with idd384 inhibitor (10.1107/S0907444900002341 )
• 1EL3: human aldose reductase complexed with idd384 inhibitor (10.1107/S0907444900002341 )
• 1IEI: crystal structure of human aldose reductase complexed with the inhibitor zenarestat. (10.1107/S0907444902002378 )
• 1MAR: refined 1.8 angstroms structure of human aldose reductase complexed with the potent inhibitor zopolrestat (10.1073/PNAS.90.21.9847 )
• 1PWL: crystal structure of human aldose reductase complexed with nadp and minalrestat (10.1002/PROT.20001 )
• 1PWM: crystal structure of human aldose reductase complexed with nadp and fidarestat (10.1002/PROT.20001 )
• 1T40: crystal structure of human aldose reductase complexed with nadp and idd552 at ph 5 (10.1107/S0907444904011370 )
• 1T41: crystal structure of human aldose reductase complexed with nadp and idd552 (10.1107/S0907444904011370 )
• 1US0: human aldose reductase in complex with nadp+ and the inhibitor idd594 at 0.66 angstrom (10.1002/PROT.20015 )
• 1X96: crystal structure of aldose reductase with citrates bound in the active site (10.1021/JM0497794 )
• 1X97: crystal structure of aldose reductase complexed with 2r4s (stereoisomer of fidarestat, 2s4s) (10.1021/JM0497794 )
• 1X98: crystal structure of aldose reductase complexed with 2s4r (stereoisomer of fidarestat, 2s4s) (10.1021/JM0497794 )
• 1XGD: apo r268a human aldose reductase (10.1016/J.BBAPAP.2005.01.006 )
• 1Z3N: human aldose reductase in complex with nadp+ and the inhibitor lidorestat at 1.04 angstrom (10.1021/JM0492094 )
• 1Z89: human aldose reductase complexed with novel sulfonyl- pyridazinone inhibitor (10.1016/J.JMB.2005.10.067 )
• 1Z8A: human aldose reductase complexed with novel sulfonyl-pyridazinone inhibitor (10.1016/J.JMB.2005.10.067 )
• 2ACQ: an anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose-6- phosphate (10.1021/BI00174A006 )
• 2ACR: an anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose-6- phosphate (10.1021/BI00174A006 )
• 2ACS: an anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose-6-phosphate (10.1021/BI00174A006 )
• 2ACU: tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and the crystal structure of the y48h mutant enzyme (10.1021/BI00174A007 )
• 2AGT: aldose reductase mutant leu 300 pro complexed with fidarestat (10.1021/JM050424+ )
• 2DUX: crystal structure of human aldose reductase complexed with zopolrestat after 3 days soaking (3days_soaked_1) (10.1016/J.JMB.2006.08.011 )
• 2DUZ: human aldose reductase complexed with inhibitor zopolrestat after 3 days soaking (3days_soaked_2) (10.1016/J.JMB.2006.08.011 )
• 2DV0: human aldose reductase complexed with zopolrestat after 6 days soaking(6days_soaked_2) (10.1016/J.JMB.2006.08.011 )
• 2F2K: aldose reductase tertiary complex with nadph and deg (10.1002/PROT.20988 )
• 2FZ8: human aldose reductase complexed with inhibitor zopolrestat at 1.48 a(1 day soaking). (10.1016/J.JMB.2006.08.011 )
• 2FZ9: human aldose reductase complexed with inhibitor zopolrestat after six days soaking. (10.1016/J.JMB.2006.08.011 )
• 2FZB: human aldose reductase complexed with four tolrestat molecules at 1.5 a resolution. (10.1016/J.JMB.2006.08.011 )
• 2FZD: human aldose reductase complexed with tolrestat at 1.08 a resolution. (10.1016/J.JMB.2006.08.011 )
• 2HV5: human aldose reductase complexed with inhibitor zopolrestat after three days soaking (3days_soaked_3) (10.1016/J.JMB.2006.08.011 )
• 2HVN: human aldose reductase-zopolrestat complex obtained by cocrystallisation after one day (1day_cocryst) (10.1016/J.JMB.2006.08.011 )
• 2HVO: human aldose reductase-zopolrestat complex obtained by cocrystallisation (10days_cocryst) (10.1016/J.JMB.2006.08.011 )
• 2I16: human aldose reductase in complex with nadp+ and the inhibitor idd594 at temperature of 15k (10.1107/S0907444906041035 )
• 2I17: human aldose reductase in complex with nadp+ and the inhibitor idd594 at temperature of 60k (10.1107/S0907444906041035 )
• 2IKG: aldose reductase complexed with nitrophenyl-oxadiazol type inhibitor at 1.43 a (10.1016/J.JMB.2006.12.004 )
• 2IKH: human aldose reductase complexed with nitrofuryl-oxadiazol inhibitor at 1.55 a (10.1016/J.JMB.2006.12.004 )
• 2IKI: human aldose reductase complexed with halogenated idd-type inhibitor (10.1016/J.JMB.2006.12.004 )
• 2IKJ: human aldose reductase complexed with nitro-substituted idd- type inhibitor (10.1016/J.JMB.2006.12.004 )
• 2INE: crystal structure of aldose reductase complexed with phenylacetic acid (10.1016/J.BIOORG.2006.09.004 )
• 2INZ: crystal structure of aldose reductase complexed with 2- hydroxyphenylacetic acid (10.1016/J.BIOORG.2006.09.004 )
• 2IPW: crystal structure of c298a w219y aldose reductase complexed with dichlorophenylacetic acid (10.1016/J.BIOORG.2006.09.004 )
• 2IQ0: crystal structure of aldose reductase complexed with hexanoic acid (10.1016/J.BIOORG.2006.09.004 )
• 2IQD: crystal structure of aldose reductase complexed with lipoic acid (10.1016/J.BIOORG.2006.09.004 )
• 2IS7: crystal structure of aldose reductase complexed with dichlorophenylacetic acid (10.1016/J.BIOORG.2006.09.004 )
• 2ISF: crystal structure of c298a w219y aldose reductase complexed with phenylacetic acid (10.1016/J.BIOORG.2006.09.004 )
• 2J8T: human aldose reductase in complex with nadp and citrate at 0.82 angstrom (10.1107/S0907444907011997 )
• 2NVC: human aldose reductase complexed with novel naphtho[1,2- d]isothiazole acetic acid derivative (3) (10.1016/J.JMB.2007.03.021 )
• 2NVD: human aldose reductase complexed with novel naphtho[1,2- d]isothiazole acetic acid derivative (2) (10.1016/J.JMB.2007.03.021 )
• 2PD5: human aldose reductase mutant v47i complexed with zopolrestat (10.1016/J.JMB.2008.03.063 )
• 2PD9: human aldose reductase mutant v47i complexed with fidarestat. (10.1016/J.JMB.2008.03.063 )
• 2PDB: human aldose reductase mutant f121p complexed with zopolrestat. (10.1016/J.JMB.2008.03.063 )
• 2PDC: human aldose reductase mutant f121p complexed with idd393. (10.1016/J.JMB.2008.03.063 )
• 2PDF: human aldose reductase mutant l300p complexed with zopolrestat. (10.1016/J.JMB.2008.03.063 )
• 2PDG: human aldose reductase with uracil-type inhibitor at 1.42a. (10.1016/J.JMB.2008.03.063 )
• 2PDH: human aldose reductase mutant l300p complexed with uracil- type inhibitor at 1.45 a. (10.1016/J.JMB.2008.03.063 )
• 2PDI: human aldose reductase mutant l300a complexed with zopolrestat at 1.55 a. (10.1016/J.JMB.2008.03.063 )
• 2PDJ: human aldose reductase mutant l300a complexed with idd393. (10.1016/J.JMB.2008.03.063 )
• 2PDK: human aldose reductase mutant l301m complexed with sorbinil. (10.1016/J.JMB.2008.03.063 )
• 2PDL: human aldose reductase mutant l301m complexed with tolrestat. (10.1016/J.JMB.2008.03.063 )
• 2PDM: human aldose reductase mutant s302r complexed with zopolrestat. (10.1016/J.JMB.2008.03.063 )
• 2PDN: human aldose reductase mutant s302r complexed with uracil- type inhibitor. (10.1016/J.JMB.2008.03.063 )
• 2PDP: human aldose reductase mutant s302r complexed with idd 393. (10.1016/J.JMB.2008.03.063 )
• 2PDQ: human aldose reductase mutant c303d complexed with uracil- type inhibitor. (10.1016/J.JMB.2008.03.063 )
• 2PDU: human aldose reductase mutant c303d complexed with idd393. (10.1016/J.JMB.2008.03.063 )
• 2PDW: human aldose reductase mutant c303d complexed with fidarestat. (10.1016/J.JMB.2008.03.063 )
• 2PDX: human aldose reductase double mutant s302r-c303d complexed with zopolrestat. (10.1016/J.JMB.2008.03.063 )
• 2PDY: human aldose reductase double mutant s302r-c303d complexed with fidarestat. (10.1016/J.JMB.2008.03.063 )
• 2PEV: complex of aldose reductase with nadp+ and simaltaneously bound competetive inhibitors fidarestat and idd594. concentration of fidarestat in soaking solution exceeds concentration of idd594. (10.1002/PROT.24136 )
• 2PF8: complex of aldose reductase with nadp+ and simaltaneously bound competetive inhibitors fidarestat and idd594. concentration of fidarestat in soaking solution is equal to concentration of idd594. (10.1002/PROT.24136 )
• 2PFH: complex of aldose reductase with nadp+ and simaltaneously bound competetive inhibitors fidarestat and idd594. concentration of fidarestat in soaking solution is less than concentration of idd594. (10.1002/PROT.24136 )
• 2PZN: the crystallographic structure of aldose reductase idd393 complex confirms leu300 as a specificity determinant
• 2QXW: perdeuterated alr2 in complex with idd594 (10.1073/PNAS.0711659105 )
• 2R24: human aldose reductase structure (10.1073/PNAS.0711659105 )
• 3BCJ: crystal structure of aldose reductase complexed with 2s4r (stereoisomer of fidarestat, 2s4s) at 0.78 a (10.1021/JM701514K )
• 3DN5: aldose reductase in complex with novel biarylic inhibitor (10.1002/CMDC.200800410 )
• 3G5E: human aldose reductase complexed with idd 740 inhibitor (10.1016/J.BMCL.2009.02.037 )
• 3GHR: human aldose reductase in complex with nadp+ and the inhibitor idd594. investigation of global effects of radiation damage on protein structure. first stage of radiation damage (10.1016/J.JMB.2009.02.030 )
• 3GHS: human aldose reductase in complex with nadp+ and the inhibitor idd594. investigation of global effects of radiation damage on protein structure. second stage of radiation damage. (10.1016/J.JMB.2009.02.030 )
• 3GHT: human aldose reductase in complex with nadp+ and the inhibitor idd594. investigation of global effects of radiation damage on protein structure. third stage of radiation damage. (10.1016/J.JMB.2009.02.030 )
• 3GHU: human aldose reductase in complex with nadp+ and the inhibitor idd594. investigation of global effects of radiation damage on protein structure. forth stage of radiation damage. (10.1016/J.JMB.2009.02.030 )
• 3LBO: human aldose reductase mutant t113c complexed with idd594 (10.1016/J.JMB.2010.11.058 )
• 3LD5: human aldose reductase mutant t113s complexed with idd594 (10.1016/J.JMB.2010.11.058 )
• 3LEN: human aldose reductase mutant t113s complexed with zopolrestat (10.1016/J.BBAGEN.2011.06.001 )
• 3LEP: human aldose reductase mutant t113c in complex with idd388 (10.1016/J.JMB.2010.11.058 )
• 3LQG: human aldose reductase mutant t113a complexed with idd388 (10.1016/J.JMB.2010.11.058 )
• 3LQL: human aldose reductase mutant t113a complexed with idd 594 (10.1016/J.JMB.2010.11.058 )
• 3LZ3: human aldose reductase mutant t113s complexed with idd388 (10.1016/J.JMB.2010.11.058 )
• 3LZ5: human aldose reductase mutant t113v complexed with idd594 (10.1016/J.JMB.2010.11.058 )
• 3M0I: human aldose reductase mutant t113v in complex with zopolrestat (10.1016/J.BBAGEN.2011.06.001 )
• 3M4H: human aldose reductase mutant t113v complexed with idd388 (10.1016/J.JMB.2010.11.058 )
• 3M64: human aldose reductase mutant t113v complexed with idd393 (10.1016/J.BBAGEN.2011.06.001 )
• 3MB9: human aldose reductase mutant t113a complexed with zopolrestat (10.1016/J.BBAGEN.2011.06.001 )
• 3MC5: human aldose reductase mutant t113v in complex with idd393 crystallized in spacegroup p1 (10.1016/J.BBAGEN.2011.06.001 )
• 3ONB: bond breakage and relocation of a covalently bound bromine of idd594 in a complex with har t113a mutant after extensive radiation dose (10.1107/S0909049511027920 )
• 3ONC: bond breakage and relocation of a covalently bound bromine of idd594 in a complex with har t113a mutant after moderate radiation dose (10.1107/S0909049511027920 )
• 3P2V: novel benzothiazepine inhibitor in complex with human aldose reductase (10.1016/J.BBAGEN.2011.06.001 )
• 3Q65: human aldose reductase in complex with nadp+ in space group p212121 (10.1074/JBC.M110.154195 )
• 3Q67: human aldose reductase c298s mutant in complex with nadp+ in space group p212121 (10.1074/JBC.M110.154195 )
• 3RX2: crystal structure of human aldose reductase complexed with sulindac sulfone (10.1016/J.FEBSLET.2011.11.023 )
• 3RX3: crystal structure of human aldose reductase complexed with sulindac (10.1016/J.FEBSLET.2011.11.023 )
• 3RX4: crystal structure of human aldose reductase complexed with sulindac sulfide (10.1016/J.FEBSLET.2011.11.023 )
• 3S3G: crystal structure of human aldose reductase complexed with tolmetin (10.1016/J.FEBSLET.2011.11.023 )
• 3T42: human aldose reductase in complex with a nitrile-containing idd inhibitor (10.1021/BI200930F )
• 3U2C: aldose reductase in complex with nsaid-type inhibitor at 1.0 a resolution (10.1002/CMDC.201100374 )
• 3V35: aldose reductase complexed with a nitro compound (10.1002/CMDC.201200333 )
• 3V36: aldose reductase complexed with glceraldehyde (10.1002/CMDC.201200333 )
• 4GCA: complex of aldose reductase with inhibitor idd 1219
• 4IGS: crystal structure of human aldose reductase complexed with nadp+ and jf0064 (10.1107/S1399004713033452 )
• 4JIR: crystal structure of aldose reductase (akr1b1) complexed with nadp+ and epalrestat (10.1016/J.FEBSLET.2013.09.031 )
• 4LAU: crystal structure of human ar complexed with nadp+ and {2-[(4- bromobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid (10.1021/CB400526N )
• 4LAZ: crystal structure of human ar complexed with nadp+ and {5-chloro-2- [(4-iodobenzyl)carbamoyl]phenoxy}acetic acid (10.1021/CB400526N )
• 4LB3: crystal structure of human ar complexed with nadp+ and {5-chloro-2- [(2-fluoro-4-iodobenzyl)carbamoyl]phenoxy}acetic acid (10.1021/CB400526N )
• 4LB4: crystal structure of human ar complexed with nadp+ and {2-[(4-bromo-2, 3,5,6-tetrafluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid (10.1021/CB400526N )
• 4LBR: crystal structure of human ar complexed with nadp+ and {5-chloro-2- [(2,6-difluoro-4-iodobenzyl)carbamoyl]phenoxy}acetic acid (10.1021/CB400526N )
• 4LBS: crystal structure of human ar complexed with nadp+ and {2-[(4-bromo-2, 6-difluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid (10.1021/CB400526N )
• 4NKC: human aldose reductase complexed with schl7764 at 1.12 a
• 4PR4: human aldose reductase complexed with schl7802 at 1.06 a
• 4PRR: human aldose reductase complexed with schl7815 ((3-[3-(5-nitrofuran-2- yl)phenyl]propanoic acid)at 1.01 a
• 4PRT: human aldose reductase complexed with schl12221 ({2-[5-(3- nitrophenyl)furan-2-yl]phenyl}acetic acid) at 0.96 a
• 4PUU: human aldose reductase complexed with a ligand with an idd structure (2-(2-carbamoyl-5-fluoro-phenoxy)acetic acid) at 1.14 a
• 4PUW: human aldose reductase complexed with a ligand with an idd structure (2-[5-fluoro-2-(prop-2-ynylcarbamoyl)phenoxy]acetic acid) at 1.12 a
• 4Q7B: human aldose reductase complexed with a ligand with an idd structure ([2-(benzylcarbamoyl)-5-fluorophenoxy]acetic acid) at 1.19 a
• 4QBX: human aldose reductase complexed with a ligand with an idd structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid) at 0.98 a
• 4QR6: human aldose reductase complexed with a ligand with an idd structure (2-[2-(1,3-benzothiazol-2-ylmethylcarbamoyl)-5-fluoro-phenoxy]acetic acid) at 1.05 a
• 4QX4: human aldose reductase complexed with a ligand with a new scaffold at 1.26 a (10.1021/JM5015814 )
• 4QXI: crystal structure of human ar complexed with nadp+ and ak198 (10.1021/ACSCHEMBIO.5B00151 )
• 4RPQ: human aldose reductase complexed with a ligand with an idd structure at 1.20 a (1)
• 4XZH: crystal structure of human aldose reductase complexed with nadp+ and jf0048 (10.1002/CMDC.201500393 )
• 4XZI: crystal structure of human aldose reductase complexed with nadp+ and jf0049 (10.1002/CMDC.201500393 )
• 4YS1: human aldose reductase complexed with a ligand with an idd structure (2) at 1.07 a. (10.1021/ACSCHEMBIO.7B00062 )
• 4YU1: human aldose reductase complexed with schl12134 (3-[5-(3-nitrophenyl)- 2-thienyl]propanoic acid) at 1.02 a
• 5HA7: human aldose reductase in complex with nadp+ and wy14643 in space group p212121 (10.1038/SREP34394 )
• 5OU0: crystal structure of human akr1b1 complexed with nadp+ and compound 37 (10.1016/J.EJMECH.2018.04.015 )
• 5OUJ: crystal structure of human akr1b1 complexed with nadp+ and compound 39 (10.1016/J.EJMECH.2018.04.015 )
• 5OUK: crystal structure of human akr1b1 complexed with nadp+ and compound 41 (10.1016/J.EJMECH.2018.04.015 )
• 6F7R: akr1b1 at 0.03 mgy radiation dose. (10.1038/S41598-019-39722-0 )
• 6F81: akr1b1 at 0.75 mgy radiation dose. (10.1038/S41598-019-39722-0 )
• 6F82: akr1b1 at 1.65 mgy radiation dose. (10.1038/S41598-019-39722-0 )
• 6F84: akr1b1 at 2.55 mgy radiation dose. (10.1038/S41598-019-39722-0 )
• 6F8O: akr1b1 at 3.45 mgy radiation dose. (10.1038/S41598-019-39722-0 )
• 6SYW: human aldose reductase in complex with sar25
• 6T27: structure of human aldose reductase mutant l301a with a citrate molecule bound in the anion binding pocket
• 6T3P: human aldose reductase mutant l300a in complex with a ligand with an idd structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
• 6T5G: structure of human aldose reductase mutant l300a with a citrate molecule bound in the anion binding pocket
• 6T7Q: human aldose reductase mutant l301a in complex with a ligand with an idd structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl) benzoic acid)
• 6TD8: human aldose reductase mutant l301a in complex with a ligand with an idd structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
• 6TUC: human aldose reductase in complex with alr25
• 6TUF: human aldose reductase in complex with alr43
• 6TXP: human aldose reductase mutant l300a in complex with a ligand with an idd structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl) benzoic acid)
• 6XUM: human aldose reductase mutant l300/301a in complex with a ligand with an idd structure ({5-fluoro-2-[(3-nitrobenzyl) carbamoyl]phenoxy}acetic acid)
• 6Y03: structure of human aldose reductase mutant l300/301a with a citrate molecule bound in the anion binding pocket
• 6Y1P: human aldose reductase mutant l300/301a in complex with a ligand with an idd structure (3-({[2-(carboxymethoxy)-4- fluorobenzoyl]amino}methyl)benzoic acid)